CN103339126B - 式(i)化合物的固态形式及其药物组合物、剂型和使用方法 - Google Patents

式(i)化合物的固态形式及其药物组合物、剂型和使用方法 Download PDF

Info

Publication number
CN103339126B
CN103339126B CN201180066359.3A CN201180066359A CN103339126B CN 103339126 B CN103339126 B CN 103339126B CN 201180066359 A CN201180066359 A CN 201180066359A CN 103339126 B CN103339126 B CN 103339126B
Authority
CN
China
Prior art keywords
formula
compound
pharmaceutical composition
spectrum
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180066359.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN103339126A (zh
Inventor
U.梅尔
N.比里
D.贝克
J.泰勒迈特
M-P.菲利奥特
T.梅斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Portola Pharmaceuticals LLC
Original Assignee
Portola Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharmaceuticals LLC filed Critical Portola Pharmaceuticals LLC
Publication of CN103339126A publication Critical patent/CN103339126A/zh
Application granted granted Critical
Publication of CN103339126B publication Critical patent/CN103339126B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201180066359.3A 2010-12-03 2011-12-05 式(i)化合物的固态形式及其药物组合物、剂型和使用方法 Expired - Fee Related CN103339126B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41956710P 2010-12-03 2010-12-03
US61/419,567 2010-12-03
PCT/EP2011/071821 WO2012072824A1 (en) 2010-12-03 2011-12-05 Pharmaceutical compositions, dosage forms and new forms of the compound of formula (i), and methods of use thereof

Publications (2)

Publication Number Publication Date
CN103339126A CN103339126A (zh) 2013-10-02
CN103339126B true CN103339126B (zh) 2016-06-29

Family

ID=45315756

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180066359.3A Expired - Fee Related CN103339126B (zh) 2010-12-03 2011-12-05 式(i)化合物的固态形式及其药物组合物、剂型和使用方法

Country Status (5)

Country Link
US (1) US8987285B2 (enExample)
EP (1) EP2646434B1 (enExample)
JP (3) JP2013544271A (enExample)
CN (1) CN103339126B (enExample)
WO (1) WO2012072824A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2961739C (en) * 2014-08-20 2024-04-30 Portola Pharmaceuticals, Inc. Lyophilized formulations for factor xa antidote
WO2017106812A1 (en) * 2015-12-19 2017-06-22 First Time Us Generics Llc Soft-chew tablet pharmaceutical formulations
US20190022013A1 (en) 2015-12-19 2019-01-24 First Time Us Generics Llc Soft-chew tablet pharmaceutical formulations
CN108883160B (zh) 2016-02-24 2022-06-28 博尔托拉制药公司 因子xa解毒剂的冻干制剂
CN110296911B (zh) * 2019-07-25 2021-09-24 天津科技大学 一种快速检测加工过程中淀粉-脂质复合物含量的方法
WO2021018730A1 (en) 2019-07-29 2021-02-04 Motherson Innovations Company Ltd. Rearview device for vehicles with circuit board

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ519984A (en) * 2000-01-07 2004-03-26 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
US6264987B1 (en) 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
US20030119060A1 (en) * 2001-08-10 2003-06-26 Desrosiers Peter J. Apparatuses and methods for creating and testing pre-formulations and systems for same
CN1923835A (zh) * 2001-12-18 2007-03-07 特瓦制药工业有限公司 氯吡格雷硫酸氢盐的多晶型
CN101300013B (zh) * 2005-11-03 2012-11-28 博尔托拉制药公司 [4-(6-卤代-7-取代的-2,4-二氧代-1,4-二氢-2h-喹唑啉-3-基)-苯基]-5-氯-噻吩-2-基磺酰脲类及与其相关的形式和方法
EP2079464A2 (en) * 2007-05-02 2009-07-22 Portola Pharmaceuticals, Inc. Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor
WO2008137809A2 (en) * 2007-05-02 2008-11-13 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl] -5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof
US20090156620A1 (en) * 2007-05-02 2009-06-18 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto
US20100151019A1 (en) * 2008-11-14 2010-06-17 Portola Pharmaceuticals, Inc. SOLID COMPOSITION FOR CONTROLLED RELEASE OF IONIZABLE ACTIVE AGENTS WITH POOR AQUEOUS SOLUBILITY AT LOW pH AND METHODS OF USE THEREOF
WO2011088152A1 (en) * 2010-01-12 2011-07-21 Portola Pharmaceuticals, Inc. Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof

Also Published As

Publication number Publication date
CN103339126A (zh) 2013-10-02
JP2018039854A (ja) 2018-03-15
US8987285B2 (en) 2015-03-24
US20130252979A1 (en) 2013-09-26
JP2016026231A (ja) 2016-02-12
EP2646434B1 (en) 2019-05-15
EP2646434A1 (en) 2013-10-09
JP2013544271A (ja) 2013-12-12
WO2012072824A1 (en) 2012-06-07

Similar Documents

Publication Publication Date Title
JP6934932B2 (ja) アンドロゲン受容体アンタゴニストの固体医薬組成物
KR102512868B1 (ko) 올라파립의 용해도 및 생체이용율이 개선된 조성물
US10441585B2 (en) Formulations containing nalbuphine and uses thereof
CN103339126B (zh) 式(i)化合物的固态形式及其药物组合物、剂型和使用方法
AU2014226292B2 (en) Solid compositions comprising a glucokinase activator and methods of making and using the same
AU2018257901A1 (en) Hsp90 inhibitor oral formulations and related methods
KR20100126452A (ko) 난용성 약물용 약학적 조성물
HUE026654T2 (en) New pharmaceutical composition comprising 4- (4- (3- (4-chloro-3-trifluoromethylphenyl) ureido) -3-fluorophenoxy) pyridine-2-carboxylic acid for the treatment of hyperproliferative disorders
KR20150080026A (ko) 테트라하이드로바이오프테린 투여 방법, 관련 조성물 및 측정 방법
TW201210591A (en) Oral dosage forms of bendamustine and therapeutic use thereof
AU2016364976A1 (en) Solid dispersions comprising a sGC stimulator
EP1849830B1 (en) Finely divided composition containing poorly water soluble substance
CA2588465C (en) Pharmaceutical composition containing an anti-nucleating agent
JP2007516188A (ja) アミスルプリドを含む新規な固形医薬組成物
US20130165459A1 (en) Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof
WO2020111089A1 (ja) 医薬組成物
JP3899522B2 (ja) 苦味が低減されたプランルカスト水和物を含有する製剤
US20230404913A1 (en) Pharmaceutical formulations for treating diseases associated with voltage-gated sodium channels
US12551491B1 (en) Dosage regimens for benzgalantamine
EP4552633A1 (en) Pharmaceutical compositions comprising amorphous solid solutions of rivaroxaban and copovidone and preparation methods thereof
JP2008094751A (ja) プランルカスト水和物含有医薬組成物
JP2026509613A (ja) （４ｓ）－２４－クロロ－４－エチル－７３－フルオロ－３５－メトキシ－３２，５－ジオキソ－１４－（トリフルオロメチル）－３２ｈ－６－アザ－３（４，１）－ピリジナ－１（１）－［１，２，３］トリアゾラ－２（１，２），７（１）－ジベンゼナヘプタファン－７４－カルボキサミドを含む医薬剤形
WO2024200335A1 (en) Pharmaceutical dosage forms comprising (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5- dioxo-14-(trifluoromethyl)-32 h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide
CN120076794A (zh) 包含纳波拉非尼的无定形固体分散体
WO2023031946A1 (en) Effervescent pharmaceutical composition of ascorbic acid and zinc

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160629

Termination date: 20191205

CF01 Termination of patent right due to non-payment of annual fee